| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
Units of 1 Molecular Cytogenetics and 2 Molecular Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy; and 3 Department of Genetics, Portuguese Oncology Institute, Porto, Portugal
Requests for reprints: Gabriella Sozzi, Molecular Cytogenetics Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, via Venezian 1, 20133 Milano, Italy. Phone: 39-02-23902232; Fax: 39-02-23902764; E-mail: gabriella.sozzi{at}istitutotumori.mi.it.
Epithelioid sarcoma is a rare soft tissue neoplasm of uncertain lineage that usually arises in the distal extremities of adults, presents a high rate of recurrences and metastases and frequently poses diagnostic dilemmas. The recently reported large-cell "proximal-type" variant is characterized by increased aggressiveness, deep location, preferential occurrence in proximal/axial regions of older patients, and rhabdoid features. Previous cytogenetic studies indicated that the most frequent alterations associated with this tumor entity affect chromosome 22. In this study, combined spectral karyotyping, fluorescence in situ hybridization, and array-based comparative genomic hybridization analyses of two proximal-type cases harboring a rearrangement involving 10q26 and 22q11 revealed that the 22q11 breakpoints were located in a 150-kb region containing the SMARCB1/INI1 gene, and that homozygous deletion of the gene was present in the tumor tissue. The SMARCB1/INI1 gene encodes for an invariant subunit of SWI/SNF chromatin remodeling complex and has been previously reported to act as a tumor suppressor gene frequently inactivated in infantile malignant rhabdoid tumors. We analyzed SMARCB1/INI1 gene status in nine additional epithelioid sarcoma cases (four proximal types and five conventional types) and altogether we identified deletions of SMARCB1/INI1 gene in 5 of 11 cases, all proximal types. We confirmed and further extended the number of cases with SMARCB1/INI1 inactivation to 6 of 11 cases, by real-time quantitative PCR analysis of mRNA expression and by SMARCB1/INI1 immunohistochemistry. Overall, these results point to SMARCB1/INI1 gene involvement in the genesis and/or progression of epithelioid sarcomas. Analysis of larger series of epithelioid sarcomas will be necessary to highlight putative clinically relevant features related to SMARCB1/INI1 inactivation.
This article has been cited by other articles:
![]() |
B. Weissman and K. E. Knudsen Hijacking the Chromatin Remodeling Machinery: Impact of SWI/SNF Perturbations in Cancer Cancer Res., November 1, 2009; 69(21): 8223 - 8230. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, C. G. Sansam, C. S. Thom, D. Metzger, J. A. Evans, P. T.L. Nguyen, and C. W.M. Roberts Oncogenesis Caused by Loss of the SNF5 Tumor Suppressor Is Dependent on Activity of BRG1, the ATPase of the SWI/SNF Chromatin Remodeling Complex Cancer Res., October 15, 2009; 69(20): 8094 - 8101. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Das, J. Cano, and G. V. Kalpana Multimerization and DNA Binding Properties of INI1/hSNF5 and Its Functional Significance J. Biol. Chem., July 24, 2009; 284(30): 19903 - 19914. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Jackson, A. J. Sievert, X. Gai, H. Hakonarson, A. R. Judkins, L. Tooke, J. C. Perin, H. Xie, T. H. Shaikh, and J. A. Biegel Genomic Analysis Using High-Density Single Nucleotide Polymorphism-Based Oligonucleotide Arrays and Multiplex Ligation-Dependent Probe Amplification Provides a Comprehensive Analysis of INI1/SMARCB1 in Malignant Rhabdoid Tumors Clin. Cancer Res., March 15, 2009; 15(6): 1923 - 1930. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chbani, L. Guillou, P. Terrier, A. V. Decouvelaere, F. Gregoire, M. J. Terrier-Lacombe, D. Ranchere, Y. M. Robin, F. Collin, P. Freneaux, et al. Epithelioid Sarcoma: A Clinicopathologic and Immunohistochemical Analysis of 106 Cases From the French Sarcoma Group Am J Clin Pathol, February 1, 2009; 131(2): 222 - 227. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. McKenna, C. G. Sansam, Y.-J. Cho, H. Greulich, J. A. Evans, C. S. Thom, L. A. Moreau, J. A. Biegel, S. L. Pomeroy, and C. W. M. Roberts Loss of the Epigenetic Tumor Suppressor SNF5 Leads to Cancer without Genomic Instability Mol. Cell. Biol., October 15, 2008; 28(20): 6223 - 6233. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Varshavsky From the Cover: Targeting the absence: Homozygous DNA deletions as immutable signposts for cancer therapy PNAS, September 18, 2007; 104(38): 14935 - 14940. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |